SE1267869T3 - - Google Patents

Info

Publication number: SE1267869T3
Authority: SE; Sweden
Prior art keywords: dependence; antagonist; tolerance; nervosa; mglur5
Prior art date: 2000-03-09

Application number

SE01910051T

Other languages

Other versions

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-09

Filing date

2001-03-09

Publication date

2004-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9887294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE1267869(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-09 Application filed filed Critical

2004-08-31 Publication of SE1267869T3 publication Critical patent/SE1267869T3/xx

2004-09-07 Publication of SE1267869T5 publication Critical patent/SE1267869T5/xx

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Addiction (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Pathology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

SE01910051T 2000-03-09 2001-03-09 SE1267869T5 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0005700.0A GB0005700D0 (en)	2000-03-09	2000-03-09	Therapy

Publications (2)

Publication Number	Publication Date
SE1267869T3 true SE1267869T3 (fr)	2004-08-31
SE1267869T5 SE1267869T5 (fr)	2004-09-07

Family

ID=9887294

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE01910051T SE1267869T5 (fr)	2000-03-09	2001-03-09

Country Status (16)

Country	Link
US (1)	US20030195139A1 (fr)
EP (1)	EP1267869B1 (fr)
JP (1)	JP2003525902A (fr)
CN (1)	CN1427720A (fr)
AT (1)	ATE267013T1 (fr)
AU (1)	AU783869B2 (fr)
CA (1)	CA2402341A1 (fr)
DE (1)	DE60103384T2 (fr)
DK (1)	DK1267869T3 (fr)
ES (1)	ES2220727T3 (fr)
GB (1)	GB0005700D0 (fr)
NZ (1)	NZ521228A (fr)
PT (1)	PT1267869E (fr)
SE (1)	SE1267869T5 (fr)
TR (1)	TR200401862T4 (fr)
WO (1)	WO2001066113A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1539149B1 (fr) *	2002-09-10	2012-01-04	Novartis AG	Combinaisons d'antagonistes des recepteurs metabotropiques du glutamate et leur utilisation pour traiter les troubles de la dependance
LT2982372T (lt)	2005-04-05	2020-10-26	Yale University	Glutamatą moduliuojantys agentai psichikos sutrikimų gydymui
WO2006121919A2 (fr) *	2005-05-05	2006-11-16	Massachusetts Institute Of Technology	Procedes de traitement de trouble obsessionnel compulsif
US7678363B2 (en)	2005-08-26	2010-03-16	Braincells Inc	Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
US7531541B2 (en) *	2005-09-20	2009-05-12	Vanderbilt University	Partial mGluR5 antagonists for treatment of anxiety and CNS disorders
CA2625153A1 (fr)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
JP2009513672A (ja)	2005-10-31	2009-04-02	ブレインセルス，インコーポレイティド	神経発生のｇａｂａ受容体媒介調節
DE102005062985A1 (de) *	2005-12-28	2007-07-05	Grünenthal GmbH	Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP2578216A1 (fr)	2006-11-22	2013-04-10	Seaside Therapeutics, Inc.	Procédés de traitement du syndrome de l'X fragile
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US20130058915A1 (en)	2010-03-02	2013-03-07	Children's Medica Center Corporation	Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (fr)	2010-05-28	2011-12-01	Xenoport, Inc.	Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et des troubles associés
US20120016021A1 (en)	2010-07-15	2012-01-19	Xenoport, Inc.	Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (fr)	2010-10-21	2012-04-26	Massachusetts Institute Of Technology	Méthodes de traitement de troubles épileptiques
US20130123254A1 (en) *	2011-09-30	2013-05-16	Barbara Biemans	Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
GB201312800D0 (en)	2013-07-17	2013-08-28	Heptares Therapeutics Ltd	mGlu5 modulators
EP3661501A1 (fr)	2017-07-31	2020-06-10	Novartis AG	Utilisation de mavoglurant dans la réduction de l'utilisation d'alcool ou dans la prévention de rechute dans l'utilisation d'alcool
CN119280233A (zh) *	2017-07-31	2025-01-10	诺华股份有限公司	玛沃谷兰在减少可卡因使用或预防复用可卡因中的用途
CN115942979A (zh) *	2020-07-17	2023-04-07	诺华股份有限公司	在减少阿片类物质使用的治疗中使用的mglur5拮抗剂玛沃谷兰
AU2021404023A1 (en) *	2020-12-14	2023-06-29	Novartis Ag	Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5958459A (en) *	1991-12-24	1999-09-28	Purdue Pharma L.P.	Opioid formulations having extended controlled released
US5543698A (en) *	1994-09-27	1996-08-06	Allen-Bradley Company, Inc.	Method and apparatus used with AC motor for detecting unbalance
GB9609976D0 (en) *	1996-05-13	1996-07-17	Lilly Industries Ltd	Pharmaceutical compounds
JP4127861B2 (ja) *	1997-03-14	2008-07-30	ジョンズホプキンスユニバーシティー	シナプス活性化タンパク質組成物および方法
TW544448B (en) *	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives
US6057368A (en) *	1998-08-05	2000-05-02	Brookhaven Science Associates Llc	Treatment of addiction and addiction-related behavior
EP1117403B1 (fr) *	1998-10-02	2003-12-10	Novartis AG	Antagonistes du mglur5 pour le traitement de la douleur et de l'angoisse
TW593241B (en) *	1999-04-20	2004-06-21	Hoffmann La Roche	Carbamic acid derivatives
AU4797400A (en) *	1999-05-17	2000-12-05	Eli Lilly And Company	Metabotropic glutamate receptor antagonists
US6666209B2 (en) *	2001-02-20	2003-12-23	3M Innovative Properties Company	Method and system of calibrating air flow in a respirator system

2000
- 2000-03-09 GB GBGB0005700.0A patent/GB0005700D0/en not_active Ceased
2001
- 2001-03-09 DE DE60103384T patent/DE60103384T2/de not_active Revoked
- 2001-03-09 JP JP2001564765A patent/JP2003525902A/ja active Pending
- 2001-03-09 PT PT01910051T patent/PT1267869E/pt unknown
- 2001-03-09 EP EP01910051A patent/EP1267869B1/fr not_active Revoked
- 2001-03-09 NZ NZ521228A patent/NZ521228A/en unknown
- 2001-03-09 DK DK01910051T patent/DK1267869T3/da active
- 2001-03-09 CA CA002402341A patent/CA2402341A1/fr not_active Abandoned
- 2001-03-09 CN CN01808891A patent/CN1427720A/zh active Pending
- 2001-03-09 AT AT01910051T patent/ATE267013T1/de not_active IP Right Cessation
- 2001-03-09 SE SE01910051T patent/SE1267869T5/xx unknown
- 2001-03-09 WO PCT/GB2001/001058 patent/WO2001066113A1/fr not_active Application Discontinuation
- 2001-03-09 TR TR2004/01862T patent/TR200401862T4/xx unknown
- 2001-03-09 US US10/221,128 patent/US20030195139A1/en not_active Abandoned
- 2001-03-09 AU AU37634/01A patent/AU783869B2/en not_active Ceased
- 2001-03-09 ES ES01910051T patent/ES2220727T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
HK1053262A1 (en)	2003-10-17
TR200401862T4 (tr)	2004-10-21
GB0005700D0 (en)	2000-05-03
CA2402341A1 (fr)	2001-09-13
JP2003525902A (ja)	2003-09-02
NZ521228A (en)	2004-04-30
SE1267869T5 (fr)	2004-09-07
DE60103384D1 (de)	2004-06-24
US20030195139A1 (en)	2003-10-16
ES2220727T3 (es)	2004-12-16
DK1267869T3 (da)	2004-09-20
WO2001066113A1 (fr)	2001-09-13
DE60103384T2 (de)	2005-06-16
AU3763401A (en)	2001-09-17
EP1267869B1 (fr)	2004-05-19
PT1267869E (pt)	2004-10-29
AU783869B2 (en)	2005-12-15
EP1267869A1 (fr)	2003-01-02
CN1427720A (zh)	2003-07-02
ATE267013T1 (de)	2004-06-15

Publication	Publication Date	Title
SE1267869T5 (fr)	2004-09-07
DE60205776D1 (en)	2005-09-29	Indolinon-derivative als protein-kinasehemmer
ES2194960T3 (es)	2003-12-01	N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
MY121136A (en)	2005-12-30	Novel heterocyclic sulfonamides.
MXPA03007140A (es)	2004-05-24	Derivados de carbolina.
DE60022692D1 (de)	2005-10-20	(S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
NZ544591A (en)	2009-07-31	Pyrrolodihydroisoquinolines as PDE10 inhibitors
MXPA03011197A (es)	2004-02-26	Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
TW200503705A (en)	2005-02-01	3-amino chroman and 2-amino tetralin derivatives
EP0986382A4 (fr)	2001-04-11	Inhibiteurs de raf kinase
DE60020595D1 (de)	2005-07-07	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE402149T1 (de)	2008-08-15	Heterozyklische substituierte amide, deren herstellung und anwendung
DE60023025D1 (de)	2006-02-16	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
AU2002358390A1 (en)	2003-06-30	Novel compounds
MXPA03007142A (es)	2004-05-24	Derivados de carbolina.
MXPA03010586A (es)	2004-04-02	N-[(1s)-1,2,3,4-tertrahidro-1-naftalenil benzamidas trisubtituidas, las cuales inhiben receptores que contienen p2x2/3.
DE60015599D1 (de)	2004-12-09	3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN
SI1377574T1 (fr)	2005-08-31
AU2002231777A1 (en)	2002-08-19	Use of mglur5 antagonists for the treatment of pruritic conditions
RS20050733A (en)	2007-06-04	Benzo/1,2,5/thiadiazole compounds
YU22802A (sh)	2005-06-10	Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
AU2002322396A1 (en)	2003-02-17	1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists
AP2000001963A0 (en)	2000-12-31	Paroxetine ascorbate.
MXPA03003926A (es)	2004-05-24	Amidas de alquinilo y sus aplicaciones terapeuticas.
DK1558610T3 (da)	2008-06-23	Substituerede aminoquinuclidinforbindelser og deres anvendelse som delta-opioidreceptorligander